



Shedding Light on Pulmonary Arterial Hypertension

The Journey Toward a Brighter Future

Pulmonary Arterial Hypertension (PAH) is a progressive disease characterized by high blood pressure in the lungs with symptoms including shortness of breath, coughing, chronic fatigue, dizziness, fainting, edema, and chest pain. These symptoms make simple physical activity very difficult, if not impossible, due to difficulty and eventual failure of the right side of the heart in pumping blood through the pulmonary artery to the lungs. PAH is believed to affect over 100,000 people of all ages and ethnic backgrounds in the US, with no known cure.

Join us as renowned physicians in the area of PAH present up-to-date information on approved and effective treatments for those living with PAH. This one-day program will consist of a CME symposium, with 3.0 category 1 credits available, for healthcare providers and two support-group programs for patients and their families. For more information on the program located in your area, please visit www.phassociation.org/medicaleducation.

September 10th — New York, New York

September 24th — Atlanta, Georgia

October 8th — Chicago, Illinois



October 15th — Seattle, Washington

October 22nd — Dallas, Texas

November 5th — Washington, DC

Sponsored by the Pulmonary Hypertension Association and CME-accredited by Dannemiller Memorial Educational Foundation.



Supported by an educational grant from Actelion Pharmaceuticals and Accredo Therapeutics.

